Skip to main content

Together we are beating cancer

Donate now
  • Health & Medicine

Capsule sponge recommended for thousands more people on the NHS in England

by Tim Gunn | News

16 November 2026

0 comments 0 comments

A pill in a petri dish. The Pill is transparent but contains a compressed black sponge. There is a light blue thread attached to one end.

A quick “pill-on-a-thread” test for helping spot oesophageal cancer could now be offered to thousands of people in England with persistent acid reflux. 

Capsule sponge tests are designed to find and monitor a condition called Barrett’s oesophagus, where stomach acid damages the cells that line the oesophagus (food pipe). 

In rare cases, these changes can lead to oesophageal cancer. Finding them can help doctors either prevent cancer or diagnose it earlier, when treatment is more likely to be successful. 

Now, drawing on evidence from Cancer Research UK-funded trials, the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending capsule sponge tests as options for: 

  1. checking for Barrett’s oesophagus in people with risk factors like acid reflux 
  2. monitoring people with Barrett’s oesophagus for signs their cells may be progressing towards cancer. 

There will now be a short consultation period before NICE finalises the recommendation. 

“Oesophageal cancer is often diagnosed late, and it is essential that we develop new ways to detect it earlier in order to improve survival,” said Michelle Mitchell, Cancer Research UK’s chief executive.  

“The capsule sponge could help support that earlier detection and diagnosis, and we’re proud to have supported its development through clinical trials.” 

An alternative to endoscopies

Capsule sponge tests are currently available in parts of the UK through pilot schemes and the BEST4 clinical trial. But until now, NICE’s overall recommendation has been for doctors in England use endoscopes, cameras on the end of flexible tubes, to diagnose and monitor Barrett’s oesophagus. 

Endoscopies are costly, time-consuming, and often uncomfortable. Replacing some with capsule sponge tests could help ease pressure on NHS services and ensure more people who need tests get them. 

Unlike endoscopies, which require at least two nurses and a specialist, the capsule sponge can be given by a doctor or nurse in a GP’s office. The Cancer Research UK-funded BEST3 trial found that this can help pick up 10 times more cases of Barrett’s oesophagus than the current standard of care. 

The test itself starts off as a small, coated pill attached to a thread. When it’s swallowed and reaches the stomach, the pill’s coating dissolves, releasing a small sponge, which expands to the size of a 50p coin. From there, a nurse or GP gently pulls the sponge out using the thread. 

As it comes out, the sponge collects a sample of cells from the lining of the oesophagus. This sample is sent to a laboratory and checked for changes associated with Barrett’s oesophagus or cancer. People whose test indicates either of those conditions are then referred for an endoscopy. 

The capsule sponge, encapsulated

Read the full story

“NICE’s proposal could bring a quicker, less invasive test to GP surgeries for some people at increased risk of oesophageal cancer, while helping NHS endoscopy services focus on those who need further investigations,” said Mitchell. 

“We look forward to the outcome of the consultation. Behind every technology like the capsule sponge are years of painstaking research, and this consultation marks an important milestone in exploring how it could make a difference for patients.”

What’s next for the capsule sponge test

The NICE consultation period will take place during the ongoing BEST4 trial, which is also investigating whether the capsule sponge could be used in a new oesophageal cancer screening programme for people with persistent heartburn. 

Cancer Research UK scientists have also been working on ways to improve the lab side of the testing process.  

Although using the capsule sponge itself is quick, it can take time for pathologists in testing labs to examine and understand the samples. As the tests are used more widely, this could create a bottleneck, potentially delaying any necessary follow ups. 

So, to tackle this, our researchers have trained an artificial intelligence (AI) model, a type of computer program that learns to recognise patterns from data, to quickly identify telltale changes within oesophageal cells and flag if Barrett’s oesophagus is present. Results so far show that this can reduce lab scientists’ workload by more than half without lowering accuracy.  

With the AI’s support, the pathologists can then spend more time on the most complex cases, where their expertise can bring the most value.  

The research team behind the AI, led by Dr Florian Markowetz at the Cancer Research UK Cambridge Institute, are now testing it on samples collected as part of BEST4.

Details on the recommendation

NICE guidance applies to NHS England directly. Welsh ministers have also issued directions requiring the NHS in Wales to follow it, unless otherwise instructed by the Welsh Government.

The recommendation does not automatically apply in Northern Ireland. It will be reviewed by the Department of Health for local applicability before being endorsed.

Scotland has a separate process for assessing and recommending healthcare technologies.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.